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Abstract Inflammatory demyelinating disease of the
central nervous system is one of the most frequent causes
of neurological disability in young adults. While in situ
analysis and in vitro models do shed some light onto the
processes of tissue damage and cellular interactions, the
development of neuroinflammation and demyelination is a
far too complex process to be adequately modeled by simple
test tube systems. Thus, animal models using primarily
genetically modified mice have been proven to be of
paramount importance. In this chapter, we discuss recent
advances in modeling brain diseases focusing on murine
models and report on new tools to study the pathogenesis of
complex diseases such as multiple sclerosis.
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Experimental autoimmune encephalomyelitis—the gold
standard
Mode of induction
Experimental autoimmune encephalomyelitis (EAE) was
first described and established as an important model of
central nervous system (CNS) autoimmune inflammation
over 50 years ago [1]. EAE can be actively induced in
susceptible inbred mice like SJL mice by immunization
with mouse spinal cord homogenate [2], myelin basic
protein (MBP; [3]), proteolipid protein (PLP; [4]) or
peptides corresponding to the major encephalitogenic
regions of MBP (MBP84–104), PLP (PLP139–151 or
PLP178–191), or myelin oligodendrocyte glycoprotein
(MOG92–106) in complete Freund’s adjuvant (CFA).
MOG makes up less than 0.5% of all myelin proteins and
is situated on the surface of myelin sheaths. MOG35–55
peptide is strongly encephalitogenic in C57BL/6 mice,
the strain providing the genetic background of most
transgenic mice. Disease induction with intact MBP or
MBP84–104 in SJL mice, and likewise with MOG35–55 in
C57BL/6 mice, requires the use of pertussis toxin (PTX)
as part of the induction regimen. PTX has been hypoth-
esized to facilitate immune cell entry into the CNS [5, 6];
however, PTX has other biological effects that could
contribute to its activity in EAE, such as breaking T cell
tolerance and promoting clonal expansion and cytokine
production by T cells [7–9]. In most murine EAE models,
after a prodromal interval of 10–20 days, paralysis of tail
and hind legs, progressing to the forelimbs, and weight
loss develop, reflecting preferential targeting of inflam-
mation to the spinal cord and to some extent the
cerebellum (referred to as “classic EAE”). Accordingly,
the scoring system is based primarily on motor deficits
resulting from spinal cord lesions. However, enhanced
brain inflammation and atypical clinical variations have
been described in murine models using certain strain/
antigen combinations or a background of genetic interfer-
on (IFN)-γ deficiency [10, 11]. Factors that can influence
the manifestation of disease are age, gender, and season at
immunization [12, 13], the preparation and physical
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structure of antigen/adjuvant emulsions [14, 15], the
species origin of the antigen [16], and epigenetic factors
[17]. The disease course of EAE depends on the strain,
immunogen, and use of PTX [18]. In the SJL (H-2s)
mouse strain, EAE displays a relapsing–remitting clinical
course (RR-EAE), while in C57BL/6 (H-2b) or PL/J and
B10.PL (H-2u) mouse strains, the disease is chronic-
progressive (C-EAE) or acute monophasic, respectively.
Alternatively to direct induction, EAE can also adoptively
be transferred to naïve mice by injection of in vitro
neuroantigen-activated T cells isolated from primed
donors [19]. The most common adoptive transfer models
involve major histocompatibility complex (MHC)-class-II-
restricted CD4+ T helper (TH) cells [20], while only a few
reports describe EAE transfer by CD8+ T cells [21, 22].
Many of the pathogenic CD4+ TH cells respond to
activation by secreting IFN-γ and tumor necrosis factor
(TNF)-α, but not interleukin (IL)-4 and IL-5, qualifying
them as TH1 cells. Recent studies, however, suggest that
this population includes a subset of CD4+ TH cells that
preferentially produces IL-17 (TH17 cells); by modifying
T cell effector functions in vitro before transfer, Langrish
and colleagues confirmed that IL-23-driven IL-17+ T cells
are highly encephalitogenic [23]. It therefore currently
appears that both TH1 and TH17 cells have pathogenic
potential [24]. Another way of manipulating the myelin-
specific T cells in vitro before transfer is the labeling by
genetic markers or fluorescent proteins/dyes, so that the
autoreactive T cells can be traced in the recipient [25, 26].
No spontaneous and naturally occurring animal models
of spontaneous EAE exist. However, T cell receptor
(TCR) transgenic mice have been generated that do not
require peptide priming and strong immune adjuvants but
spontaneously develop EAE with variable incidence.
Although the immunological repertoire in TCR transgenic
mice is significantly altered and biased towards enhanced
antigen-specific responses and alternative mechanisms of
immune regulation [27, 28], studies using such transgenic
models have contributed significantly to the understanding
of the pathogenesis of CNS autoimmunity. Various TCR
transgenic models of EAE on different genetic back-
grounds exist, including humanized mice carrying human
leukocyte antigen (HLA) class II molecules associated
with multiple sclerosis (MS) susceptibility and TCR [29–
31]. Interestingly, HLA-DRB1*0401-restricted MBP111–129-
specific humanized TCR transgenic mice display clinical
signs of inflammatory demyelination in brain stem and
cranial nerve roots, like dysphagia in addition to ascend-
ing paralysis typical of EAE [31]. 19G B10.PL (H-2u)/
MBPAc1-11, [27], 5B6 SJL (H-2
s)/PLP139–151 [32], and
2D2 C57BL/6 (H2-b)/MOG35–55 TCR transgenics [33] are
spontaneous models utilizing mouse MHC class II
restriction elements. The clinical spectrum displayed
varies from classical hind limb paralysis to isolated optic
neuritis (2D2 TCR transgenics in the C57BL/6 strain). A
large percentage of MOG35–55 TCR transgenic mice
crossed to MOG-specific immunoglobulin heavy chain
knock-in animals spontaneously develop a Devic-like,
opticospinal disease [34, 35].
Pathogenesis (priming and CNS invasion)
Classical models of EAE are mainly driven by MHC-
class-II-restricted CD4+ T lymphocytes [36–38]. Active
and passive induction protocols both activate peripheral
myelin-specific CD4+ T cells that have escaped immune
tolerance and circulate in the periphery of naïve animals
(reviewed in [39]). During the induction phase of actively
induced EAE, myelin-reactive CD4+ T cells are primed
and expand in the peripheral lymphoid organs. In contrast,
in the adoptive transfer model of EAE, disease is induced
by the peripheral introduction of a preactivated population
of myelin-epitope-specific CD4+ T cells to a naïve mouse.
The effector phase involves migration of activated myelin-
specific T cells to the CNS, where they cross the blood–
brain barrier (BBB). CNS-infiltrating CD4+ T cells require
myelin peptides presented by local antigen-presenting
cells (APCs) for full reactivation [40, 41]. Recently, also
dendritic cells (DCs) have been demonstrated to be the
initial APCs for encephalitogenic T cells to recognize their
target antigen (Ag)/organ [42, 43]. The reactivated CD4+
T cells then initiate a cascade of events, including the
secretion of chemokines, that recruit predominantly
macrophages to the site of inflammation. Proinflammatory
cytokines secreted by macrophages, such as TNF-α and
IL-1, are important for both perpetuating inflammation
and contributing to CNS tissue damage [44]. Microglia are
also activated in EAE and blocking microglial activation
suppresses the development of EAE, supporting their
pathogenic role in CNS autoimmune disease [45–48].
The function of astrocytes in disease pathogenesis remains
unclear, as they show proinflammatory activity by producing
neurotoxic mediators, cytokines, and chemokines but also
exert neuroprotective functions by providing neurotrophic
factors (reviewed in [49–51]). After CNS tissue is damaged,
epitope spreading is believed to occur by the release and
subsequent presentation of endogenous myelin epitopes by
local APCs [26, 52] and has been shown to mediate clinical
relapses in certain EAE models [53, 54].
Mouse, rat, monkey background
EAE is mainly studied in the highly reproducible
murine model, as mice are inbred and a genetically
homogenous population. Furthermore, transgenic and
targeted gene deletion murine models are abundant,
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and numerous reagents are available that can be used to
dissect the pathogenic mechanisms in EAE. Neverthe-
less, EAE has been replicated in a wide range of
species, and the different species and strains offer
different advantages. EAE induced in rabbits or guinea
pigs with CNS myelin is similar to MS in that
inflammation occurs in both the brain and spinal cord
[55, 56]. To investigate the contribution of demyelinating
antibodies, EAE models in guinea pig [57], common
marmoset [58], and certain rat and mouse models [16, 59]
have been proven to be useful.
EAE is induced in the marmoset by immunization with
CNS tissue homogenate or recombinant MOG in CFA
(reviewed in [60]) and provides a disease model that
reproduces several clinical and pathological features of
MS. Adoptive and passive transfer experiments indicate
that, similar to MOG-induced EAE in the rat, synergism
between encephalitogenic T cells and demyelinating anti-
bodies is required for full lesion formation [58, 61]. In
spite of variable disease induction in the outbred marmo-
set species and limited availability of reagents, the
marmoset model may have some value for drug testing
considering that it is phylogenetically closer to humans
than rodents.
Histopathological findings—man versus mouse
Histopathological changes seen in EAE appear to represent
a stereotypic response of the CNS to autoimmune damage.
While EAE, as many other disease models, certainly is not
a full mirror image of MS, it comes pretty close to what can
be seen in human MS lesions. However, the clinical
features, including the pattern of disease progression and
the histopathology, may vary depending on (1) the species
in which disease is provoked as well as (2) the approach of
EAE induction (for review, see [62]).
Early and/or acute MS lesions in humans are character-
ized by demyelination (Fig. 1a, b), extensive macrophage
invasion (Fig. 1c, d), perivascular and parenchymal T cell
infiltrates (Fig. 1g, h), and few B cells/plasma cells as well
as relative axonal preservation. While ongoing remyelina-
tion next to demyelination is a typical feature of active MS
lesions [63], based on the myelin loss, extent of oligoden-
drocyte preservation, and composition of the inflammatory
infiltrates, four distinct—admittedly descriptive—histopath-
ological patterns of acute MS lesions have been suggested
[64] and await final clinical validation. In brief, common
feature of these acute lesions is the predominance of macro-
phages, which are ∼10 times more frequent than, e.g., T cells
(the latter are mainly of the CD8+ phenotype). On top of
which, some lesions (referred to as pattern II) display activated
complement on dying myelin sheaths and in macrophages,
while others (so-called pattern III) are described to have a
preferential loss of the myelin-associated glycoprotein (for
review, see [65]). Recent data also point to a crucial role of
DCs, which due to their close proximity to invading T cells
adjacent to CNS vessels (Fig. 1f, g, h) seem to be crucial
APCs in conferring CNS inflammation of encephalitogenic
T cells [42]. In contrast to acute MS lesions, chronic MS
plaques display extensive and sharply demarcated white
matter lesions with variable axonal loss and significant
fibrillary astrogliosis; due to only few residual lymphocytes
and macrophages/microglia, these chronic lesions appear to
be “burnt out” (for review, see [65]).
Acute EAE lesions in mice—the species which we
primarily refer to—histopathologically resemble the peri-
vascular macrophage-/microglia-rich inflammatory pattern
of acute/chronic active MS lesions in humans (Fig. 2),
while severe demyelination is seen rather in chronic
relapsing EAE models (for review, see [62]).
Due to the high reproducibility of EAE lesions with
respect to cellular composition and histopathological
appearance, animal models of EAE are most valuable in
studying pathogenetically relevant consequences of defined
manipulations. Moreover, such lesions can be studied at
any time point, which explains why EAE models also in
terms of histopathology are a most precious addition to the
repertoire of modern MS research tools.
Use of transgenic mice to unravel pressing questions
about the pathogenesis of CNS inflammation; knockout
mice
Specific mouse genes can routinely be overexpressed as
transgenes or eliminated by gene targeting (“knockouts”),
which allows a “clean” and direct assessment of the
causative roles of certain molecules in disease pathogenesis.
Various transgene constructs involving targeted expression
of MHC/costimulatory molecules or alterations of the TCR
repertoire towards a highly autoreactive population have
been designed to challenge the immune system’s mecha-
nisms of self-tolerance [66]. Studies in transgenic and
knockout mice have implicated a number of effector
molecules such as cytokines, chemokines, and other
proteins in MS [67]. The conventional approach has several
disadvantages; transgene expression may have direct toxic
effects on the target tissue and be insensitive to regulatory
networks, and in particular, normal developmental kinetics
cannot be mimicked, as expression is either “on” or “off”
from time of developmental onset (reviewed in [68–71]).
Further (conditional) techniques have been developed to
limit manipulated gene expression to defined cell types
(Cre-loxP system of site-specific recombination [72]) and
specific time points. Commonly used examples for such a
spatial and temporal control of genes of interest are the
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tetracycline-controlled transactivator system [73] and the
tamoxifen-controlled expression of Cre (CreERT2, [74]).
CNS-specific expression can be induced, e.g., by promoter
regions encoding glial fibrillary acidic protein (GFAP),
neurofilament, MBP, or MOG which are expressed in
astrocytes, neurons, and oligodendrocytes, respectively.
The nestin-Cre transgene mediates excision of loxP-
flanked sequences in early neuronal precursors during
embryonic life, resulting in target gene inactivation in all
neuroectodermal cells of the CNS [75]. CNS-targeted
manipulations of cytokine/chemokine expression offer a
relatively nonintrusive technique for assessment of their
role (reviewed in [68, 76]). In vivo cell lineage ablation,
e.g., of MOG+ oligodendrocytes, has recently been im-
proved by stable mouse lines, carrying conditional expres-
sion constructs for diphtheria toxin (DT) or DT receptor
(DTR) that could be activated upon Cre-mediated recombi-
nation and the application of DT, respectively [77]. CD11b-
herpes simplex virus thymidine kinase (HSVTK) transgenic


















HLA class II CD209
*
* * * * * ** *** ***
*




Fig. 1 Histopathology of acute and/or chronic active MS lesion: severe
demyelination (H&E (a); LN, Luxol-Nissl (b)) and numerous CD163+
(c) or CD68+ (d) macrophage and microglia-rich inflammatory
infiltrates including prominent perivascular inflammation are predom-
inant histopathological findings. Gray and white matter in a and b is
separated by asterisks. Rectangles represent the area chosen for
higher-magnification analysis throughout. While strong HLA class II
immunoreactivity (e) was present throughout the MS lesion, CD209+
cells (f) were mainly restricted to vessels and seen in close proximity
to invading CD3+ (g) and CD4+ (h) T cells. Scale bar 400 μm (a, b),
100 μm for all other panels. Adapted from [42]









Fig. 2 Spinal cord cross sections of wild-type mice displaying an
acute perivascular EAE lesion (H&E, arrows), mainly consisting of
activated Iba1+ macrophages/microglia (second and, at higher
magnification, third row). Impairment of myelinated (Luxol-Nissl,
LN; fourth row) and axonal structures (neurofilament, NF, fifth row),
while indicated due to the early state is not yet fully developed (and
better visible in chronic lesions). Scale bars 100 µm for first, third,
fourth, and fifth column; 100 µm for second, fourth, and sixth column.
Adapted from [96]
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have been generated as a tool to study the impact of
microglial activation on CNS disease in vivo. Expression of
HSVTK renders preferentially proliferating cells sensitive to
ganciclovir, as the active metabolite competes with thymine
for DNA synthesis [45]. To dissect APC functions in the
CNS parenchyma versus the periphery, gene targeting can
also be combined with bone marrow chimerism [42].
Astrocyte activation during EAE in vivo was monitored
by Luo and colleagues by the use of bioluminescence
imaging in mice expressing luciferase under the control of a
GFAP promoter [78]. “Knock-ins” of functional cytokine
genes have been ligated to green fluorescent protein (GFP)
for cell tracking of cytokine-producing cells [79]. Based on
the linked expression of GFP to Foxp3+ T cells, two groups
have generated Foxp3gfp.KI mice in order to reliably
monitor regulatory T cells (T-reg) in vivo [80, 81]. Taken
together, the true strength of the mouse model is its
capacity to intervene with the pathogenesis of inflammatory
CNS disease at the molecular level and to prove or mostly
dismiss hypothesis about the involvement of specific
molecules in the inflammatory cascade.
Cytokines and mediators of inflammation
Upon cognate antigen recognition on an activated APC, T
cells become polarized towards an effector type depending on
the quality of priming immune synapse and the cytokines
present. Signaling of certain signature cytokines results in
lineage commitment towards one of the three effector types,
termed TH1, TH2, or TH17. The classic paradigm, proposed
by Mosmann and Coffman in 1986, strictly divided effector
TH cells into TH1 cells, directing cell-mediated immunity,
and TH2 cells, regulating B cell activity and humoral
immunity [82]. TH1 cells produce primarily IFN-γ and
IL-2, while IL-4 and IL-5 are produced by TH2 cell. Lineage
commitment employs autocrine loops for “self-propagation”
and reciprocal inhibition via their cytokines. In addition to
the TH1-promoting effects of IFN-γ itself, TH1 cells are
predominantly polarized by the APC-derived factors IL-12
and IL-18 [83]. The TH1/TH2 paradigm provided a concep-
tional framework which shaped our understanding of
communication pathways during adaptive immune response.
Over the years, TH1 cells were found to be the main culprits
behind CNS inflammation, primarily based on the fact that
inflammatory CNS lesions and invading T cells produced
IFN-γ. In MS patients, elevated levels of IL-12p40 mRNA
were detected in the CNS [84], while in the animal model
EAE such TH1 cells were shown to actually infiltrate the
CNS in great numbers and produce their effector cytokines
when CNS inflammation occurred. Purified TH1 cells could
be transferred into naive animals and mediate autoimmune
disease. Conversely, TH2 cells were shown to exert
beneficial effects in EAE (reviewed in [85]).
Given the overwhelming case for TH1 cells and IFN-γ, it
was surprising at first that in mice none of the TH1 and TH1-
inducing cytokines (IFN-γ, IL-12, IL-18, TNF-α) could
account for the proposed importance of the TH1 effector cells
in the disease [86–89]. Even though functional studies could
hardly verify the pivotal role of TH1 cells in autoimmu-
nity, the model was not abandoned but clearly dominated
common belief for decades. A tangible alternative was
proposed with the discovery that the IL-12 family member
IL-23 instead of IL-12 itself is a prerequisite for the
development of EAE [87, 90, 91]. The central role of IL-
23 in EAE was proven by Sedgewick and colleagues by
the deletion of the p19 subunit of IL-23 [91]. The
particular impact connected to this finding was the
description of a novel TH cell effector type, which showed
IL-23-dependent expansion and expression of the proin-
flammatory cytokine IL-17A [23]. They were therefore
coined TH17 cells. IL-23- and IL-6-deficient mice showed
impaired TH17 polarization. In consequence, it seems that
such loss rendered the mice resistant to EAE [24]. A
plethora of data was generated that correlated TH17 cells
and IL-17A expression with the development of autoim-
mune inflammation in mice and humans (reviewed in
[92]). Almost forgotten was the fact that in most respects
TH1 cells and TH1 cytokines correlate just as well with
autoimmune disease and that adoptive transfer of TH1
cells for the passive induction of EAE was the standard
procedure for years.
Surprisingly, IL-17A neutralization in EAE in C57BL/6
mice by Hofstetter et al., however, only revealed a very
mild effect of treatment with either monoclonal antibodies
against IL-17A or with the soluble receptor of IL-17A and
F [93]. IL-17A−/− mice were generated by the group of
Iwakura and found to be fully susceptible to EAE after
active immunization but demonstrate an alleviated course
of clinical EAE in the chronic phase of disease [94]. Even
more surprisingly, these findings were then interpreted by
others to represent the clear and solid proof that IL-17A is
the key player in CNS autoimmune inflammation in mice
and probably in men as well. The slight change in the
course of EAE found upon deletion of IL-17A certainly
confirms its proinflammatory properties at the site of an
active autoimmune lesion but, nonetheless, fails to mark it
as an essential encephalitogenic factor. Haak et al. and
Kreymborg et al. have by now dismissed the TH17
cytokines IL-17A, IL-17F, and IL-22 as critical players in
the EAE pathogenesis [95, 96]. After an initial confusion in
the field, it remains a solid fact that IL-23 is vital for EAE
development while TH17 cells and their cytokines display a
great deal of redundancy. Recently, McGeachy et al. and
Gyülvészi et al. reported that IL-23 promotes the CNS
tropism of encephalitogenic Tcells [97, 98]. The mechanistic
underpinnings of this phenomenon remain to be established.
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Hence, while we have clear evidence that a certain quality
of T cell effector function permits encephalitogenic T cells
access into the CNS, the precise molecular signature
remains to be established.
BBB biology and leukocyte trafficking to the CNS
Under physiological conditions, a limited number of
leukocytes enter the CNS (referred to as immune surveil-
lance; [99]). In the course of EAE, BBB dysfunction is
associated with increased leukocyte extravasation across
CNS postcapillary venules and subsequent leukocyte
accumulation in the perivascular space forming inflamma-
tory cuffs. In postcapillary venules, the endothelial cell
monolayer and underlying basement membrane, ensheath-
ing astrocyte end feet, leptomeningeal cells, and their
associated parenchymal basal membrane all contribute to
the BBB [100]. Therefore, EAE presents an excellent
model to study leukocyte migration across the BBB into
the CNS during autoimmune inflammation. Several tech-
niques have been developed to assess the disruption of the
BBB in situ, like immunohistochemical analysis for tight
junction proteins, serum-derived proteins (fluorescein iso-
thiocyanate albumin leakage assay, [101]), or Evans Blue
diffusion [102, 103]. In vivo tracing studies using geneti-
cally or fluorescently labeled leukocytes have been com-
bined with intravital microscopic analysis to study
interactions with superficial brain microvasculature [104].
Finally, to further elucidate molecular mechanisms of CNS
trafficking neutralizing antibodies, small molecule inhib-
itors or (endothelial specific) transgenic/knockout models
of trafficking determinants like adhesion molecules can be
used [105].
In EAE, intravital fluorescence videomicroscopy has
revealed an integrin α4- and P-selectin-dependent rolling of
leukocytes along CNS vessels, without the involvement of
E-selectin as in other tissues [106] and an integrin α4β1
(very late antigen-4, VLA-4)-mediated, G-protein-
independent capture of T cells at the endothelial cell surface
[104, 107]. The integrin α4β1 ligand, vascular cell
adhesion molecule (VCAM-1), as well as intercellular
adhesion molecule 1 (ICAM-1), and activated leukocyte
cell adhesion molecule (ALCAM) are well-described adhe-
sion molecules expressed on inflamed BBB endothelial cells
and seem to be important for leukocyte transmigration
[108, 109]. The realization that integrinα4β1/VCAM-1 inter-
actions play a crucial role in leukocyte adhesion to the BBB
has led to the development of natalizumab, a humanized
anti-α4-integrin antibody, as an effective novel drug for the
treatment of MS [110, 111]. More recent data indicate that
α6β1 integrin, the major receptor of laminin 4, mediates T
lymphocyte migration across the endothelial basement
membrane. Elimination of laminin 4 or α6β1 integrin
resulted in reduced T cell infiltration and EAE severity
[112]. Functional expression of CCL19 and CCL21 occurs
in CNS venules surrounded by inflammatory cuffs, and these
lymphoid chemokines have been implicated in T lymphocyte
migration across the endothelial cell monolayer [113].
Previous studies have suggested that subsequent migra-
tion out of the perivascular cuff and into the CNS
parenchyma requires the classical inflammatory chemo-
kines, including CCL2 [114–116]. Further, leukocytes use
focal matrix metalloproteinase (MMP-2 and MMP-9)
activity to penetrate the parenchymal basement membrane
[117].
Models of CD8-mediated EAE
Attention has long been focused on CD4+ T cells because
susceptibility of MS is associated with MHC class II genes
[118], and CD4 T cells are critical to the induction in most
EAE models [119]. However, CD8+ T cells have also been
implicated in MS by their higher number and invasiveness
into the parenchyma compared to mainly perivascularly
clustered CD4+ T cells in MS lesions [65, 120–122], their
clonal expansion based on TCR analysis [123, 124], and
their pathogenicity in certain EAE models [22, 125, 126],
whereas in other models, CD8+ T cell may play a
regulatory role and protect against the disease development
[123, 127–129]. Data showing that CD8+ T cells can, in
some conditions, directly attach to and transect axons
support the idea that CD8+ T cells mediate damage [130].
CD4 bias after immunization
Due to the method of induction of classical EAE with
CNS-derived antigen emulsified in adjuvants which favors
a CD4+ T cell bias in the population of responding
myelin-specific T cells, EAE is not an ideal model to
investigate the contribution of CD8+ T cells to disease.
The most important component in the adjuvant CFA is
heat-inactivated Mycobacterium tuberculosis, which indu-
ces a prominent MHC-class-II-restricted CD4+ TH1
response [131, 132].
Myelin-specific CD8+ T cells can adoptively transfer
EAE, thereby establishing a pathogenic role for CD8+ T
cells in EAE and providing a model for analysis of CD8+ T
cells in MS. In a study by Huseby et al., adoptive transfer
of MBP-specific CD8+ T cells isolated from wild-type C3H
mice mediated severe CNS autoimmunity [21]. The
symptoms resembled many features of MS not seen in
CD4+ T-cell-mediated EAE models, such as ataxia,
spasticity, hyperreflexiveness, and loss of coordinated
movements. CNS demyelinating lesions predominated in
the brain versus the spinal cord, which was quite distinct
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from most CD4+ T-cell-mediated models of EAE in which
the lesions are mainly found in the spinal cord. Perivascular
cuffs were composed of lymphocytes, macrophages, and a
few neutrophils. CD8+ T-cell-mediated CNS autoimmunity
was independent of CD4+ T cells and largely inhibited by
neutralizing IFN-γ activity. Two other groups successfully
induced CD8+ T-cell-mediated EAE in C57BL/6 mice by
transferring CD8+ T cells specific for MOG37–46 into
syngeneic mice [22, 126].
Transgenic models (auto versus neo Ag)
Several transgenic mouse models have been developed to
study the pathogenic role of CD8+ T cells in autoimmune
CNS inflammation. Brisebois and colleagues have recently
shown that endogenous CD8+ T cells were necessary for
the development of full-blown neuroinflammation in mice
overexpressing the costimulatory ligand CD86 on microglia
cells [133]. The majority of T cells in the CNS of mouse
mutants that overexpress PLP in oligodendrocytes
expressed CD8 [134].
Other systems have employed TCR transgenic T cells
recognizing natural or model brain autoantigens in an
MHC-class-I-restricted manner. In GFAP–hemagglutinin
(HA) × CL4-TCR double transgenic mice, in which the
viral (neoself) antigen influenza HA is specifically
expressed in astrocytes and enteric glia and in which most
CD8+ T cells are HA specific, early death due to an attack
on enteric glial cells precluded the analysis of EAE
development [135]. Adoptive transfer of HA-specific
CD8+ T cells resulted in immune cell infiltration in the
brains of transgenic mice, expressing HA in astrocytes,
but failed to induce clinical CNS disease [136]. In H-2K-
restricted MBP79–87 TCR transgenic mice, MBP-specific
CD8+ T cells sufficed to induce CNS autoimmunity, but
immune tolerance prevented these autoreactive cells from
causing disease [137]. Transgenic mice expressing a
Borna disease virus (BDV) antigen in either neurons or
astrocytes were also tolerant to the neoself antigen. In this
model, however, adoptive transfer of activated BDV-
specific CD8+ T cells was sufficient to induce disease,
which was attributed to the high viral antigen concen-
trations in the CNS [138].
Mice in which the model antigen influenza HA is
selectively expressed in oligodendrocytes have been gener-
ated (DKI) to test whether autoreactive CD8+ T cells can
contribute to the loss of oligodendrocytes as observed in
MS plaques. Crossing these mice to CL4-TCR transgenic
mice did not result in spontaneous neuroinflammation, and
CL4-TCR transgenic CD8+ T cells rather seemed to remain
“indifferent” to the neoself antigen sequestered in the CNS.
However, transfer of preactivated HA-specific CD8+ T
cells in DKI mice led to inflammatory lesions in the optic
nerve, spinal cord, and brain [139]. In another study,
intracerebral injection of the influenza virus HA512–520
peptide in soluble form in CL4-TCR transgenic mice
initiated CNS infiltration by the circulating HA-specific
CD8+ T cells. It was suggested that peptide-loaded MHC
class I molecules expressed on the luminal side of
endothelial cells at the BBB might have triggered transmi-
gration [140]. A similar model for CNS-specific autoim-
munity employed ovalbumin (OVA) sequestered as a
neoself antigen in the cytosol of oligodendrocytes.
Introduction of the MHC-class-I-restricted, OVA-specific
OT-I TCR as a second transgene led to spontaneous
fulminant demyelinating EAE with MS-like lesions,
affecting cerebellum, brainstem, optic nerve, and spinal
cord. Endogenously generated OT-1 TCR transgenic
CD8+ T cells were highly encephalitogenic, which
seemed to depend on a BBB, permeable for naïve CD8
T cells during the first 10 days of life and on the
production of IFN-γ. In contrast, OVA-specific CD4+ T
cells (OT-II), remained fully ignorant of the self-antigen
unless OT-I TCR Tg CD8+ T cells first released OVA
from oligodendrocytes for peripheral presentation [141].
Recently, a role for HLA-A-restricted CD8+ T cells in the
pathogenesis of an MS-like disease was also demonstrated
in humanized mouse models [142, 143].
Infection-induced CD8 expansion
CD8+ T cells are key mediators in the immune response to
many viral infections, and a role for CD8+ T cells in
demyelination has been illustrated in viral models of CNS
inflammation. CD8+ T cells are essential for clearance of
virus but might also become pathogenic and damage CNS
tissue. Several mechanisms have been described to explain
how viruses might trigger autoimmune disease including
adjuvant effects and the provision of viral antigens that are
similar to self-antigens and stimulate cross-reactive immune
responses (molecular mimicry; reviewed in [144]). Models
of molecular identity, although artificial, showed that an
immune response to a viral infection could recognize
identical antigens presented as self in the CNS, resulting
in overt CNS autoimmune disease [145, 146]. During
lymphocytic choriomeningitis virus (LCMV) infection,
LCMV-specific CD8+ T cells expand greatly [147, 148].
Evans and colleagues generated transgenic mice that
expressed the nucleoprotein or glycoprotein of LCMV as
self in oligodendrocytes. After peripheral (but not CNS)
infection with LCMV, the virus was efficiently cleared, but
a chronic CNS autoimmune disease developed character-
ized by T cell inflammatory lesions with mainly CD8+ T
cells, areas of focal myelin loss, marked upregulation of
MHC class I and II molecules, and clinical motor
dysfunction. Autoimmune responses in the CNS developed
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despite the fact that LCMV was not detectable in the CNS,
demonstrating that autoimmunity can occur at a site distal
to the initiating infection [145]. In other models of
molecular identity/mimicry, autoimmune disease is induced
by infection with a nonpathological Theiler’s murine
encephalomyelitis virus (TMEV) variant that was engi-
neered to express the immunodominant self-epitope from
myelin PLP peptide (PLP139–151) [146] or viral peptides
that mimic PLP139–151 [149]. Other studies focusing on
viral infections of the CNS have revealed that T cells under
certain circumstances are able to bypass recognition of
peptide–MHC complexes and mediate tissue destruction
without TCR engagement [150, 151]. Haring and col-
leagues used transgenic TCR/RAG2−/− mice with only T
cells that are not specific for mouse hepatitis virus to show
that activated CD8+ T cells are able to cause bystander
tissue damage even in the absence of cognate antigen in the
CNS [150].
Theiler virus and models of demyelination
TMEV-induced demyelinating disease
TMEV, murine hepatitis virus, and Semliki Forest virus are
useful models for understanding the potential viral etiology
of MS (reviewed in [152]). Intracerebral infection of
susceptible strains of mice, such as SJL, with natural
TMEV leads to either rapidly fatal encephalomyelitis (high-
neurovirulence strains) or persistent CNS infection and
immune-mediated demyelination (low-neurovirulence
strains, BeAN, or DA; [153, 154]). Gait disturbances,
spastic hind limb paralysis, and urinary incontinency start
30–40 days after infection. Intracerebral injection of virus
leads to persistent CNS infection. The level of infectious
virus is low during the chronic phase, but abundant
amounts of viral RNA and antigen can be detected
throughout the lifetime of the mouse [155–157]. During
the acute phase of the disease, virus replication is mainly
in neurons, whereas during the chronic phase, TMEV
persists predominantly in macrophages and glia [155,
158–160]. Virus particles have been identified in oligo-
dendrocytes which have a “dying back” pathology [161].
TMEV virus is known to cause demyelination in infected
nude mice that cannot generate mature T lymphocytes
[162], also pointing to a direct viral effect on myelin
damage.
Upon TMEV infection, a variety of chemokines and
cytokines are induced in primary astrocytes via the nuclear
factor κB pathway including TNF-α, IL-1, IL-6, CCL2, and
CCL5 [163–165]. Inflammatory responses to TMEV
infection seem to depend on toll-like receptor (TLR)3 and
TLR2 [166, 167], as well as protein kinase R, signaling
[168]. The immune response is initially directed against
persistent viral antigens, but the chronic phase of the
disease is dependent on de novo activation of autoimmune
CD4+ T cell responses against CNS myelin that develop
locally as a result of the release of myelin antigens, i.e.,
epitope spreading [26, 169–171]. In SJL mice, reactivity
appears to multiple myelin peptides starting with the
immunodominant epitope and spreading later to other
subdominant myelin determinants in a hierarchical manner
[170, 172]. Resistance to persistent CNS infection by
TMEV is controlled by multiple genetic loci, with the
strongest linkage to the class I H-2D MHC region [173,
174], which indicates a role for CD8+ T cells. Most
evidence points towards a protective function of CD8+ T
cells via the clearance of TMEV from the CNS [175–178];
however, there is also evidence that MHC-class-I-restricted
CD8+ T might be directly cytotoxic to axons and mediate
injury [179, 180].
Cuprizone and lysolecithin, demyelination without
autoimmunity
Several toxin-based models of demyelination, including
cuprizone and lysolecithin, while not attempting to accu-
rately mimic the pathogenesis of autoimmune CNS inflam-
mation, have proven very useful to study the mechanisms
of demyelination and remyelination. In contrast to the
systemically administered cuprizone, the membrane-
solubilizing, glia-toxic lysolecithin has been used to create
focal areas of demyelination by direct injection into defined
CNS white matter tracts, which allows for a better control
of lesion size and location (reviewed in [181]).
Feeding of cuprizone (bis(cyclohexanone)-oxaldihydra-
zone) to young adult mice induces a consistent, synchro-
nous, and anatomically reproducible demyelination.
Furthermore, removal of cuprizone of the diet of mice
leads to remyelination (reviewed in [182]). Cuprizone is a
chelator that binds copper, an essential component of
metalloenzymes, like the mitochondrial cytochrome oxi-
dase and monoamine oxidase. It has been assumed
although not proven that copper deficiency results in
specific damage to oligodendrocytes in the CNS and
subsequent demyelination. The specific susceptibility of
oligodendrocytes has been attributed to the high metabolic
demand of these glial cells required to maintain a vast
expanse of myelin and the resulting vulnerability to a
disturbed energy metabolism.
Genetic factors and gender influence susceptibility to
cuprizone-induced demyelination [183]. Cuprizone can
induce demyelination in different strains of mice, among
them in 8–10-week-old C57BL/6 mice, the background
most commonly used for knockout and transgenic mice. A
0.2% dose of cuprizone is usually well tolerated. If
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cuprizone is overdosed, (mitochondrial) hepatopathy and
weight loss are serious toxic effects [184]. The regional
pattern of demyelination includes white matter tracts
preferentially the corpus callosum, as well as the cerebellar
peduncles [185]. More recently, cortical demyelination has
been detected [186], and demyelination in the hippocampal
formation has been associated with seizures in the cupri-
zone model [187, 188]. Substantial demyelination is present
starting after 3 weeks of cuprizone, and by 4–5 weeks more
than 90% of axons will be demyelinated. Under continued
exposure of cuprizone, about 50% of axons recover and are
remyelinated by 6 weeks. If cuprizone is discontinued by
this time, recovery continues, so that by 10 weeks 90% of
the axons are remyelinated. If, in contrast, the cuprizone
challenge is retained, demyelination again dominates so
that few myelinated fibers remain [182]. During cuprizone
toxicity, there is also demyelination-associated axonal loss
which is more prominent in aged mice [189]. Reduction in
average axon caliber and some dystrophic neurites are
observed [190, 191]. Demyelination/remyelination is pref-
erentially quantitated by ultrastructural analysis performed
by electron microscopy, which is best to evaluate the
number of myelinated axons, thickness of the myelin
sheath, and relationship to the axon size. Histochemical
lipid staining with Luxol Fast Blue–periodic Schiff or
immunostaining for myelin proteins allows us to estimate
and screen for myelination semiquantitatively. Biochemical
(lipid) assays analyze the content of the myelin sheath
[192]. Magnetic resonance imaging (MRI) has been used to
map the pattern of demyelination noninvasively [193].
During administration of cuprizone, the expression of
myelin genes in the brain decreases, and most of the
mature oligodendrocytes in the corpus callosum, the site of
particular profound demyelination, undergo apoptosis
[194]. Studies of changes in oligodendrocyte precursor
and mature oligodendrocyte dynamics suggest that oligo-
dendrocyte precursors drive the repopulation of oligoden-
drocytes in the remyelination phase [194]. Oligodendrocyte
precursor cells are detectable in the corpus callosum,
presumably proliferate, and convert to mature glutathione
S-transferase (GST)-Π+ oligodendrocytes during remyeli-
nation [194], sequentially expressing myelin proteins
[195].
In contrast to EAE, the BBB seems to remain intact
[196, 197]; T cells are almost completely absent, and
microglia/macrophages accumulate and predominate in the
demyelinated areas [198, 199]. Bone marrow studies
indicate that resident microglia outnumbers peripheral
macrophages that are recruited in cuprizone-induced CNS
demyelination [197]. Studies using lymphocyte-deficient
RAG-1 mice have demonstrated that lymphocytes may not
play a role in the cuprizone model [200, 201]. Microglia/
macrophages are the main cell type responsible for clearance
of myelin debris and are able to secrete a wide variety of
cytokines. Analysis of MHC-II-null mice showed reduced
inflammation, delayed remyelination, and regeneration of
oligodendrocytes, whereas removal of MHC I had little
effect [201, 202]. Macrophage depletion by treatment with
clodronate liposomes throughout the remyelination phase
significantly decreases the extent of oligodendrocyte
remyelination following lysolecithin-induced demyelin-
ation [203]. Various inflammatory products, including
IFN-γ, IFN-β, leukemia inhibitory factor, lymphotoxin-α,
lymphotoxin-β, IL-1β, nitric oxide, insulin-like growth
factor, and macrophage inflammatory protein 1α, have
been studied in the cuprizone model and have been shown
to have a deleterious or protective role [204–214]. TNF-α
seems to be protective, promoting proliferation, differentia-
tion of oligodendrocyte progenitors (bromodeoxyuridine-
labeled NG2+ cells), and subsequent remyelination [200].
Thus, induction of MHC II by TNF-α has been suggested as
an important regulatory event in remyelination, emphasizing
the active inflammatory response in brain regeneration after
brain injury [202].
Neuropathological changes observed during cuprizone
treatment correlate with alterations in the neurological
function such as hyperactive behavior and mild motor
dysfunction detectable by sensitive motor tests [215,
216].
Model of lipopolysaccharide-induced demyelination
A number of studies have examined the effects of
lipopolysaccharide (LPS) injections into the CNS [217–
220]. Typically, a local inflammatory reaction is evoked but
substantially muted when compared with similar injections
in other tissues [217]. Felts et al. described an inflammatory
reaction and after a delay of 5–7 days a demyelinating
lesion that arise following the injection of LPS into rat
spinal white matter [219, 220] and that persist between 9
and 14 days. Besides activation of resident microglia, CNS-
infiltrating phagocytes (neutrophils and monocytes) seem to
contribute to the inflammatory response [221], although
injecting LPS or leukocyte chemotaxis into the CNS seems
to induce a lower myelomonocytic recruitment compared to
other tissues [217, 222]. Microglial TLR4 is required for
leukocyte recruitment into the brain in response to LPS
[223]. The exact mechanism of LPS-induced demyelination
is unknown. In primary mixed glial cultures, LPS induces a
selective loss of oligodendrocyte precursors, and activation
of microglia, but not astrocytes, is required for LPS toxicity
[224, 225]. Conditioned media from LPS-exposed micro-
glia (or astrocytes) injures oligodendrocyte progenitors
[226]. TLR4 is necessary for LPS-induced oligodendrocyte
injury in the CNS, although mRNA for the LPS receptors
TLR4/CD14 is either absent or only found at very low levels
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in oligodendrocyte precursors [224]. Thus, LPS might not be
directly toxic to oligodendrocytes but cause demyelination via
factors derived from activated microglia/macrophages (or
astrocytes). Accordingly, recent evidence suggests that micro-
glial peroxynitrite (the reaction product of nitric oxide and
superoxide anion), or in the presence of astrocytes activation
of TNF/TNFR signaling, play a key role in LPS-induced
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Fig. 3 DT-mediated ablation of oligodendrocytes in MOGi-Cre/iDTR
mice: cerebella of DT-treated (+DT, first and second column) MOGi-
Cre/iDTR mice present with a severe destruction of myelinated
structures, as visualized by Luxol-Nissl (LN) and CNPase stains.
Untreated (−DT) iMOG-Cre/iDTR mice (second and third column)
were unaffected. Axonal integrity was affected in DT-treated iMOG-
Cre/iDTR mice (neurofilament immunohistochemistry) and some
inflammatory cells (HE) and a mild reactive astrogliosis (GFAP) were
visible in DT-treated iMOG-Cre/iDTR mice. Rectangles indicate the
adjacent high-magnification image. Scale bar 500 μm for first and
third column; 100 μm for second and fourth column. Adapted from
[77]
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oDTR mice
The means for specific in vivo cell lineage ablation have
recently been improved by stable mouse lines, carrying
conditional expression constructs for DT or DTR that could
be activated upon Cre-mediated recombination and the
application of DT, respectively [77, 228]. In Cre-inducible
DTR transgenic mice (iDTR) Cre-mediated excision of a
STOP cassette renders cells sensitive to DT. DT crosses the
BBB and promotes cell ablation in the CNS. Injecting DT
intraperitoneally into MOGi-Cre/iDTR double transgenic
mice expressing Cre recombinase under the control of the
oligodendrocyte-specific promoter MOG results in a severe
myelin loss throughout the CNS [77]. Axonal integrity
subsequently also appears to be affected, and some reactive
astrogliosis as well as inflammatory cells are seen (Fig. 3).
After approximately 30 days, the DT-treated MOGi-Cre/
iDTR mice present clinically with tremor, hind limb
paralysis, and weight loss (Fig. 4; Table 1).
Concluding remarks
Taken together, there is now a plethora of different animal
models available, each of them serving the purpose to study
specific aspects of the pathogenesis of MS in rodents.
Whereas these models are most useful and have provided a
wealth of knowledge otherwise unavailable to us, there are
a number of limitations in regards to interpreting the data.
A number of questions cannot be directly answered in
animal models including the initial trigger of the MS
pathogenesis (vaccination with autoantigen is hardly to
blame), the driving self-Ag, the genetic predisposition, and
others. Therefore, none of the described animal models can
truly serve for drug testing or replace clinical trials. To this
day, the animal models described here are the state-of-the-
art and the very best modeling system available to us. We
need to be cautious not to overinterpret the findings and to
continue to create better models to accurately study certain
aspects of the pathogenesis of neuroinflammatory disease.
Table 1 Commonly used MS models
Model Mode of induction Pathomechanism Phenotype
EAE -Immunization CD4+ T-cell-mediated Myelitis (>cerebellitis)
-Adoptive transfer (CD4+) ” ”
-Spontaneous → (humanized) TCR
Tgs (MHCII-restricted)
”
•2D2 MOG35-55 TCR Tgs
× MOG-specific IgH KI
” Optic neuritis [33]
CD4+ T/B-cell-mediated Devic-like disease [34]
-In rats/marmosets (MOG)
[in (conditional) Tg/KO mice]
T cell/antibody-mediated Encephalomyelitis
CD8+ AT -Adoptive transfer (CD8+) CD8+ T-cell-mediated Brain > spinal cord [21]
•TCR Tgs (MHCI-restricted)
× auto/neo brain ag [spontaneous]
” Encephalomyelitis
TMEV-IDD -Intracerebral infection Virus-induced demyelination Encephalomyelitis
Cuprizone -Feeding Toxin-based demyelination Corpus callosum, cerebellar
peduncles [185]












































Fig. 4 Induction and effector
stage of MS/murine models.
Abbreviations: EAE, experi-
mental autoimmune encephalo-
myelitis; AT, adoptive transfer;
TMEV-IDD, Theiler’s murine
encephalomyelitis virus-induced
demyelinating disease; TCR, T
cell receptor; Tg, transgenic; KI,
knock-in, KO, knockout; TH, T
helper cell; BBB, blood–brain
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